title: [Imiquimod: the biochemical mechanisms of immunomodulatory and anti-inflammatory activity].
abstract: Imidazoquinolins represent a new group of compounds that recently entered into clinical practice as anti-tumor and anti-viral immune modulators. They are low molecular weight synthetic guanosine-like molecules. Although imiquimod, the most widely used imidazoquinolin, is recommended for the treatment of several forms of skin cancer and papillomas, the molecular mechanisms of its action are not fully understood. In particular, imiquimod has been characterized as a specific agonist of Toll-like receptor 7 (TLR7) and is widely used in this capacity in a large number of experimental studies and clinical trials. However, detailed analysis of the published data with the use of imiquimod, suggests that its biological activity can not be explained only by interaction with TLR7. There are indications of a direct interaction of imiquimod with adenosine receptors and other molecules that regulate the synthesis of cyclic adenosine monophosphate. A detailed understanding of the biochemical basis of imiquimod immunomodulating and antitumor effect will increase its clinical effectiveness and accelerate the development of new drugs with similar but improved medical properties. This review summarizes the published data concerning the effects of imiquimod on a variety of intracellular biochemical processes and signaling pathways.
authors.forename: S V
authors.initials: SV
authors.lastname: Bozrova
authors.forename: V A
authors.initials: VA
authors.lastname: Levitskiĭ
authors.forename: S A
authors.initials: SA
authors.lastname: Nedospasov
authors.forename: M S
authors.initials: MS
authors.lastname: Drutskaia
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000634:Aminoquinolines / Q000627:therapeutic use*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D006801:Humans; D000077271:Imiquimod; D009363:Neoplasm Proteins / Q000819:agonists / Q000378:metabolism; D010212:Papilloma / Q000188:drug therapy*; D058906:Purinergic P1 Receptor Agonists / Q000627:therapeutic use*; D018047:Receptors, Purinergic P1 / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D012878:Skin Neoplasms / Q000188:drug therapy*; D051199:Toll-Like Receptor 7 / Q000819:agonists / Q000378:metabolism
chemical_list: D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D000894:Anti-Inflammatory Agents, Non-Steroidal; D009363:Neoplasm Proteins; D058906:Purinergic P1 Receptor Agonists; D018047:Receptors, Purinergic P1; C495348:TLR7 protein, human; D051199:Toll-Like Receptor 7; D000077271:Imiquimod